A recent study published in the New England Journal of Medicine found that Ozempic helped seven out of 10 patients newly diagnosed with type 1 diabetes stop taking insulin after three to six months
Tirzepatide is a dual agonist acting on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
Its active ingredient is semaglutide the same molecule found in Wegovy (FDA-approved for chronic weight management) and Rybelsus (oral daily tablet for diabetes)
Functionally, it behaves like naturally occurring peptide hormones by interacting with receptors that regulate metabolism, appetite, and insulin secretion
Niagen Bioscience CEO Rob Fried explains nicotinamide riboside (NR), Tru Niagen, and new at-home injections, IVs, and NAD+ formats
For someone managing type 2 diabetes, this means blood glucose levels creep upward